ArticleJournal of Parkinson's disease2013
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics.
Article in Journal of Parkinson's disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.Annals of neurology · 2024Article
- The Parkinson's Disease Composite of Executive Functioning: A Measure for Detecting Cognitive Decline in Clinical Trials.Neurology · 2024Article
- Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra.Annals of clinical and translational neurology · 2024Article
- Allogenic microglia replacement: A novel therapeutic strategy for neurological disorders.Fundamental research · 2024Review
- Illusory Responses across the Lewy Body Disease Spectrum.Annals of neurology · 2023Article
- Gait and balance in apolipoprotein Ɛ4 allele carriers in older adults and Parkinson's disease.Clinical parkinsonism & related disorders · 2023Article
- Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure.Frontiers in aging neuroscience · 2023Article
- Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Cognition as a mediator for gait and balance impairments in GBA-related Parkinson's disease.NPJ Parkinson's disease · 2022Article
- Interval timing and midfrontal delta oscillations are impaired in Parkinson's disease patients with freezing of gait.Journal of neurology · 2022Article
- A Metabolomic Aging Clock Using Human Cerebrospinal Fluid.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Predictive Modeling of Alzheimer's and Parkinson's Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid.Metabolites · 2022Article
- Increased Basal Ganglia Modulatory Effective Connectivity Observed in Resting-State fMRI in Individuals With Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinson's disease.Journal of clinical and experimental neuropsychology · 2021Article
- Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinson's Disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2021Article
- Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ.Parkinsonism & related disorders · 2021Article
- Single-cell peripheral immunoprofiling of Alzheimer's and Parkinson's diseases.Science advances · 2020Article
- Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis.Acta neuropathologica communications · 2020Article
- Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.Brain : a journal of neurology · 2020Article
- Resting-State Cerebello-Cortical Dysfunction in Parkinson's Disease.Frontiers in neurology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe substantial proportion of individuals with Parkinson's disease (PD) who have or are expected to develop concomitant cognitive impairment emphasizes the need for large, well-characterized participant cohorts to serve as a basis for research into the causes, manifestations, and potential treatments of cognitive decline in those with PD.
objectiveTo establish a multi-site clinical core that cognitively and clinically characterizes patients with PD by obtaining quality longitudinal clinical, neuropsychological, and validated biomarker data.
methodsSix hundred nineteen participants with idiopathic PD (68.0 ± 9.1 years, 7.1 ± 6.2 years since diagnosis, 70% males) were enrolled in the Pacific Northwest Udall Center (PANUC), one of the Morris K. Udall Centers of Excellence for Parkinson's Research, Clinical Consortium and underwent comprehensive clinical and neuropsychological assessment. Participants were diagnosed with no cognitive impairment (PD-NCI), mild cognitive impairment (PD-MCI), or dementia (PDD) at a diagnostic consensus conference.
resultsA substantial proportion of the overall sample was diagnosed with cognitive impairment at baseline: 22% with PDD and 59% with PD-MCI. A higher rate of cognitive impairment was observed in men than women (87% vs. 68%, p < 0.0001), despite a higher level of education. Most patients older than 50 years at the time of diagnosis and with disease duration greater than 10 years were cognitively impaired or demented.
conclusionsThe PANUC Clinical Consortium is a clinically and cognitively well-characterized cohort of patients with PD. Baseline cohort characteristics demonstrate a high rate of cognitive impairment in the sample, as well as potential sex differences with regard to cognitive diagnosis. The PANUC Clinical Consortium, with its access to biomarker, genetic, and autopsy data, provides an excellent foundation for detailed research related to cognitive impairment in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.